V. Comparison Between the Oxygen Enhancement Rations for Neutrons and X Rays, as observed withEscherichia coliB

Dr Tikvah Alper: a short history of her scientific career

PURPOSE

This article can only skim the surface of an extraordinary career of Dr Alper from the early days in South Africa and throughout her life.

CONCLUSIONS

She overcame many obstacles to become widely acknowledged as having had an immense effect on the study of radiation biology. Her very considerable personal scientific achievements in no way prevented her from taking time to help and inspire others in the field as well as maintaining a long and happy family life. If an example is needed to show what can be achieved with a combination of total intellectual integrity and determined application, then Tikvah Alper certainly provided this.

Importance of hypoxia in the biology and treatment of brain tumors

The resistance of gliomas to treatment with radiation and antineoplastic drugs may result in part from the effects of the extensive, severe hypoxia that is present in these tumors. It is clear that brain tumors contain extensive regions in which the tumor cells are subjected to unphysiological levels of hypoxia. Hypoxic cells are resistant to radiation. Hypoxia and the perfusion deficits and metabolic changes that accompany hypoxia in vivo also produce resistance to many commonly used anticancer drugs. The resistance of cells that are hypoxic at the time of therapy may influence the efficacy of the treatment of these tumors with radiation, chemotherapy, and combined modality regimens. Moreover, it is becoming increasingly evident from laboratory studies that exposure of cells to adverse microenvironments produces transient changes in gene expression, induces mutations, and selects for cells with altered genotypes, thus driving the evolution of the cell population toward increasing malignancy and increasingly aggressive phenotypes. Hypoxia may therefore be involved in the evolution of cells in low-grade malignancies to the resistant, aggressive phenotype characteristic of glioblastomas. During the past 50 years, many attempts have been made to circumvent the therapeutic resistance induced by hypoxia, by improving tumor oxygenation, by using oxygen-mimetic radiosensitizers, by adjuvant therapy with drugs that are preferentially toxic to hypoxic cells, by using hyperthermia, or by devising radiation sources and regimens that are less affected by hypoxia. Past clinical trials have provided tantalizing suggestions that the outcome of therapy can be improved by many of these approaches, but none has yet produced a significant, reproducible improvement in the therapeutic ratio, which would be needed for any of these approaches to become the standard therapy for these diseases. Several ongoing clinical trials are addressing other, hopefully better regimens; it will be interesting to see the results of these studies.

Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy

The clinical work with chemical agents to restore the radiosensitivity of hypoxic cells began in 1973 with metronidazole, misonidazole was first given in 1974. The results so far recorded of the clinical trials with misonidazole have been generally disappointing. Only in 5 of 32 studies analyzed have significant benefits been shown to suggest real advantage with the use of misonidazole. Hypoxic cells must exist in all human tumours presenting for treatment and it is, however, probable that the oxygen effect is an important one at all dose fractionation regimes employed in radiotherapy but, after conventional fractionated radiotherapy, hypoxia may be a reason for failure in only a proportion of cases. The most important factor underlying the failure of misonidazole to achieve useful advantage is undoubtedly the low radiosensitizing concentrations achievable with the permitted dose of this neurotoxic drug. New drugs are under development and some have different dose-limiting toxicity. Those showing promise at this time are the Stanford compound, SR-2508, which is being extensively studied in the United States and the Roche compound, Ro 03-8799, which is being studied in the United Kingdom. It is possible that the greatest sensitization with the greatest tolerance will be achieved by a combination of drugs.

A tumor/normal tissue advantage for low dose rate neutron brachytherapy

Reports on clinical study of Cf-252 pelvic brachytherapy are reviewed and show that complication frequency is low. Low dose rate (LDR) neutron brachytherapy has been shown to be effective against cervical and advanced pelvic cancers; and produces 5 year cures without a high frequency of normal tissue complications. This is attributed to a high relative biological effectiveness (RBE) for the bulky, hypoxic tumor which along with an oxygen enhancement ratio (OER) advantage and dose-rate independent effects, produces rapid tumor regression and good local tumor control. Adjacent normal tissues which are oxygenated have lower RBE values than that of hypoxic tumors. Cf-252 brachytherapy increases the dose differential, therapeutic gain and the probability of local tumor control, since the high RBE of Cf-252 for hypoxic tumor is much less in normal tissues. Cf-252 radiation concentrated in the tumor, and for this reason, has had much fewer attendant normal tissue complications compared to neutron beam therapy.

Fractionated dose of 35-MEV fast neutrons and hypoxic tumor cell survival curve

The determination of the RBE for the MANTA fast neutrons produced by NRL is inprogress, with the model system using tumor cell population kinetic response patterns assayed in vitro after irradiation in vivo. Ascites tumor cells BW-5147 were irradiated with a clinically usable fast neutron beam from the NRL cyclotron, which is produced by accelrating deuterons to 35 MeV and using htem to bombard a thick berylliumtarget. The comparison of dose-effect relationships was made for doses ranging from30 to 1000 rads. The doses required for an isoeffect on BW-5147 hypoxic tumor cell survival and impairment of its reproductive capacity from fast neutron exposure were not different wheither it was given a single dose or the same dose given in three fractions separated by long recovery periods in situ. No intracellular repair of sublethal injury when the dose was given in three fractions, although the hypoxic BWp5147 tumor cells haveno effective reoxygenation or repopulation in this time interval. The RBE for the fast neutron beam is 4 relative to x rays for fractionated doses at the surviving fractionlevel of 0.6-0.7, while the RBE IS 2.5 FOR SINGLE DOSES. However, at a surviving fraction of 0.1, the RBE is 1.9 for single and 2.8 for fractionated doses. Analysis of thedaily cell population rate or mitotic delay between the two types of radiations at a similiar level of survival.

A Model for the Study of X-ray and Neutron Effects on Tumor Cell Populations

This work deals with the mathematical formulation of a model for studying the effects of X-ray and fast-neutron irradiation on tumor cell populations, the end-effect being the inhibition of reproductive integrity. The variables considered in such a model are largely based on original work performed on trasplantable tumors and obtained in part from other published data; they regard: a) The sensitivity of the tumor cell population with respect both to the extrapolation number and to the slope of the exponential part of the survival curve. b) The type of radiation used, allowing for different RBE values under oxygenated or anoxic conditions. c) The oxygen-enhancement ratios of the radiations considered. d) Different modalities of irradiation (single and multiple doses), allowing for cell recovery in the latter case. e) Different modalities of fractionation with respect to the magnitude of the dose delivered at each fraction. f) The degree of anoxia and the percentage of anoxic cells in the tumor population. g) Possible variations in the percentage of anoxic cells at various points along the course of the radiation treatment. The results of this theoretical analysis are presented, both with regard to the shape of the survival curve of the total cell population and to dose-cure-rate tables, under each of the above-mentioned conditions. Finally, the possible advantages and limitations of the use of neutrons in clinical radiotherapy are briefly discussed.